Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

The islet amyloid polypeptide (amylin or diabetes associated peptide or insulinoma amyloid peptide or IAPP) targeted pipeline therapeutics report provides comprehensive information on the islet amyloid polypeptide targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in islet amyloid polypeptide targeted therapeutics development with respective active and dormant or discontinued projects.

What are the key mechanism of actions in the islet amyloid polypeptide targeted pipeline therapeutics market?

The key mechanism of actions in the islet amyloid polypeptide targeted pipeline therapeutics market are islet amyloid polypeptide activator and islet amyloid polypeptide inhibitor.

Islet amyloid polypeptide targeted pipeline therapeutics market, by MoA

Islet amyloid polypeptide targeted pipeline therapeutics market, by MoA

For more MoA insights, download a free sample

What are the key route of administration in the islet amyloid polypeptide targeted pipeline therapeutics market?

The key route of administration in the islet amyloid polypeptide targeted pipeline therapeutics market are subcutaneous, intravenous and oral.

key route of administration in the islet amyloid polypeptide targeted pipeline therapeutics

key route of administration in the islet amyloid polypeptide targeted pipeline therapeutics

For more RoA insights, download a free sample

What are the key molecule type in the islet amyloid polypeptide targeted pipeline therapeutics market?

The key molecule type in the islet amyloid polypeptide targeted pipeline therapeutics market are synthetic peptide, recombinant peptide, small molecule, monoclonal antibody, and peptide.

key molecule type in the islet amyloid polypeptide targeted pipeline therapeutics market

key molecule type in the islet amyloid polypeptide targeted pipeline therapeutics market

For more molecule type insights, download a free sample

What are the key companies in the islet amyloid polypeptide targeted pipeline therapeutics market?

The key companies in the islet amyloid polypeptide targeted pipeline therapeutics market are ADM Therapeutics, Adocia SAS, Eli Lilly and Co, Gubra ApS, Intarcia Therapeutics Inc, Neurimmune Holding AG, Nordic Bioscience AS, ProMIS Neurosciences Inc, reMYND NV, Wren Therapeutics Ltd, and Zealand Pharma AS.

key companies in the islet amyloid polypeptide targeted pipeline therapeutics market

key companies in the islet amyloid polypeptide targeted pipeline therapeutics market

To know about more key companies, download a free sample

Market report overview

Key route of administration Subcutaneous, Intravenous and Oral
  Islet Amyloid Polypeptide Activator and Islet Amyloid Polypeptide Inhibitor
Key molecule type Synthetic Peptide, Recombinant Peptide, Small Molecule, Monoclonal Antibody, and Peptide
Key companies ADM Therapeutics, Adocia SAS, Eli Lilly and Co, Gubra ApS, Intarcia Therapeutics Inc, Neurimmune Holding AG, Nordic Bioscience AS, ProMIS Neurosciences Inc, reMYND NV, Wren Therapeutics Ltd, and Zealand Pharma AS

 Scope

  • The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)
  • The report reviews Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

ADM Therapeutics
Adocia SAS
Eli Lilly and Co
Gubra ApS
Intarcia Therapeutics Inc
Neurimmune Holding AG
Nordic Bioscience AS
ProMIS Neurosciences Inc
reMYND NV
Wren Therapeutics Ltd
Zealand Pharma AS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) – Overview

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) – Companies Involved in Therapeutics Development

ADM Therapeutics

Adocia SAS

Eli Lilly and Co

Gubra ApS

Intarcia Therapeutics Inc

Neurimmune Holding AG

Nordic Bioscience AS

ProMIS Neurosciences Inc

reMYND NV

Wren Therapeutics Ltd

Zealand Pharma AS

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) – Drug Profiles

(exenatide + glucagon + pramlintide) – Drug Profile

Product Description

Mechanism Of Action

(insulin aspart + pramlintide) – Drug Profile

Product Description

Mechanism Of Action

(insulin lispro + pramlintide) – Drug Profile

Product Description

Mechanism Of Action

History of Events

AC-253 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ADM-116 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Amylin – Drug Profile

Product Description

Mechanism Of Action

DACRA-089 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GUI-17 – Drug Profile

Product Description

Mechanism Of Action

GUI-35 – Drug Profile

Product Description

Mechanism Of Action

ITCA-1061 – Drug Profile

Product Description

Mechanism Of Action

KBP-056 – Drug Profile

Product Description

Mechanism Of Action

KBP-088 – Drug Profile

Product Description

Mechanism Of Action

History of Events

NI-203 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ReS-39 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit IAPP for Neurodegenerative Diseases and Pancreatic Diseases – Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptide for Obesity and Type 2 Diabetes – Drug Profile

Product Description

Mechanism Of Action

History of Events

Synthetic Peptides to Inhibit ABPP and IAPP for Alzheimer’s Disease and Type 2 Diabetes – Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides to Target IAPP for Obesity and Diabetes – Drug Profile

Product Description

Mechanism Of Action

ZP-5461 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ZP-8396 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) – Dormant Products

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) – Discontinued Products

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) – Product Development Milestones

Featured News & Press Releases

Nov 04, 2021: Zealand Pharma announces first subject dosed in phase 1 trial of amylin analogue ZP8396 for the treatment of obesity

Nov 01, 2021: Zealand Pharma announces presentation of preclinical data on amylin analogue ZP8396 at The Obesity Society Annual Meeting

Jun 29, 2021: Adocia initiates BC LisPram phase 1 clinical trial in pump for people with type 1 diabetes

Jun 14, 2019: ADA2019: Find the two Adocia abstracts including the “BioChaperone Glucagon Exenatide” Poster online

Jun 04, 2019: Adocia presents on BioChaperone Pramlintide Insulin at the American Diabetes Association® 79th Scientific Sessions

Feb 12, 2019: Adocia to present new clinical data on Pramlintide-Prandial Insulin combinations at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)

Sep 05, 2018: Adocia announces positive topline results for the first clinical study of BioChaperone Pramlintide Insulin in people with type 1 diabetes

Apr 16, 2018: Adocia initiates First-in-Human Clinical Study of BioChaperone Pramlintide Insulin in people with type 1 diabetes

Apr 03, 2018: Taming an unruly target in diabetes

Jan 05, 2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes

May 05, 2014: reMYND’s novel diabetes treatment prevents – and even reverses – disease progression in pre-clinical diabetes models

Apr 10, 2013: Centennial Lecture features research on restoring memory and movement

Dec 11, 2012: University Of Alberta Medical Researchers Make Key Discovery In Fight Against Alzheimer’s Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by ADM Therapeutics, 2022

Pipeline by Adocia SAS, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by Gubra ApS, 2022

Pipeline by Intarcia Therapeutics Inc, 2022

Pipeline by Neurimmune Holding AG, 2022

Pipeline by Nordic Bioscience AS, 2022

Pipeline by ProMIS Neurosciences Inc, 2022

Pipeline by reMYND NV, 2022

Pipeline by Wren Therapeutics Ltd, 2022

Pipeline by Zealand Pharma AS, 2022

Dormant Projects, 2022

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.